This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

MarketVIEW: Universal Pneumo Vaccines





NEW YORK, Feb. 18, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

MarketVIEW: Universal pneumo vaccines

http://www.reportlinker.com/p0961710/MarketVIEW-Universal-pneumo-vaccines.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

Vaccines to prevent serious infections caused by Streptococcus pneumoniae or "pneumo" currently form the largest component of the global vaccine market ( $4 - 5bn/yr). Notable examples are Prevnar/Prevenar (PCV7) first marketed to cover the seven most common US serotypes causing infant invasive pneumococcal disease (IPD) and now recently extended to a new 13-valent form (PCV13). Pfizer vaccines (formerly Wyeth) are also expanding PCV13 indications into older age groups especially those with underlying co-morbidities who are currently vaccinated with 23-valent Pneumovax (PPSV). Pneumococcal vaccines are being rolled out to GAVI-funded markets in developing countries where the burden of pneumo related diseases is more extreme. 

The ultimate Pneumo vaccine would be able to prevent disease covered by the majority of ~90 serotypes, cheap to produce and therefore available on a global scale. Investigators in both the commercial and academic/not-for-profit sector are investigating these "universal" protein-based vaccines (PUPV) which could eventually replace conjugated forms although many development challenges remain. 

This MarketVIEW product is a comprehensive opportunity assessment focused on understanding the commercial potential of new "universal" protein-based vaccines should they be licensed. As well as an Executive presentation, the product contains two detailed value/volume forecast models at the country level which detail all the latest dynamics between product forms and all target groups being in mind evolution in US/EU/ROW policy recommendations. The possible entry of new PUPV(s) is then modelled and current development issues/approaches discussed. 

THIS PRODUCT IS A EXECUTIVE PRESENTATION + 2 MODELSContents – Executive presentation (MS PowerPoint based)Author's noteExecutive SummaryPneumo vaccines: key model model outputsAll pneumo vaccines: available market ($000s) to 2030All pneumo vaccines: estimated volume ('000s doses) to 2030Pneumo vaccines by type: available market ($000s) to 2030Pneumo vaccines by type: available infant market ($000s) to 2030Pneumo vaccines by type: all adult market (HI) ($000s) to 2030Pneumo vaccines: adult market 65yrs+ (HI) ($000s) to 2030Pneumo vaccines: adult market 18-64yrs (HI) ($000s) to 2030Pneumo vaccines by type: all adult market (LO) ($000s) to 2030Pneumo vaccines: adult market 65yrs+ (LO) ($000s) to 2030Pneumo vaccines: adult market 18-64 yrs (LO) ($000s) to 2030Pneumo vaccines: available market ($000s) to 2030 by vaccine typePneumo vaccines: key model assumptionsMarkets covered to 2030Populations modelled: per age segmentKey model assumptions: product entry and switchingPricing assumptions applied overallPricing assumptions applied per countryPricing: reimbursement, private/private splitAdult Pneumo indications and vaccination policiesAdult Pneumo indications: definition of risk segmentsAdult Pneumo indications: risk groups % of 18-64 yrs cohortAdult Pneumo indications and vaccination policies: per countryPCV13: adult roll-out assumptionsPUPV: roll-out overall rationalePUPV: roll-out assumptions per countryCompany reported sales analysisPneumo vaccines: company reported sales analysisCompany reported sales analysis by vaccine typeCompany reported sales analysis by region (cont...)Epidemiology of pneumococcal diseaseBacterial meningitis per age group (child)/pathogen US 2003-2007*Bacterial meningitis per age group (adult)/pathogen US 2003-2007Epidemiology of pneumococcal disease: post vaccine eraEpidemiology of pneumococcal disease: impact of PCV in USEpidemiology of pneumococcal disease: non PCV7 serotypes (UK)Epidemiology of pneumococcal disease: non PCV13 serotypes (UK)Epidemiology of pneumococcal disease: mortality per serotypeVaccine coverage rates: infantsVaccine coverage rates: adultsNew Pneumo vaccines: brief overview of current R&DConcept of a protein based pneumo vaccinePUPV: ideal product profileGSK2189242A: recombinant-conjugated vaccineGSK2189242A: Gambia trialSanofi Pasteur: multi-protein based PUPVSanofi Pasteur: PUPV Bangladesh trialCurrent commercial pneumo vaccine pipeline (clinical)Novel pneumo protein antigensPATH – new pneumococcal vaccine developmentPATH – pneumo vaccine project: overview of collaboratorsBibliographyDisclaimerAbout VacZine AnalyticsPAGES: ~70 MS PowerPoint slides, fully referenced/sourced. Available in .pdf formContents – Vaccine demand model(s) (MS Excel-based)***NOTE*** - there are 2 models (LO & Hi scenarios) each with ~ 90 individual sheetsTitle sheetImportant notesCharts – ValCharts – VolGRAND VALUE SUMMARYPCV Vol/ValPPSV Vol/ValPUPV Vol/Val0 – 2 yrs per countryUS infantCanada infantUK infantGermany infantFrance infantItaly infantSpain infantBelgium infantNetherlands infantGreece infantPortugal infantPoland infantOther Europe infantAustralia infantJapan infantSouth Korea infantOther high income infantBrazil infantMexico infantTurkey infantOther UMI infantOther UMI infant (upside)GAVI active infantGAVI planned infant18 – 49 yrs per countryUS "at risk" Canada "at risk"UK "at risk" Germany "at risk" France "at risk" Italy "at risk" Spain "at risk" Belgium "at risk" Netherlands "at risk" Greece "at risk" Portugal "at risk" Poland "at risk"Other Europe "at risk" Australia "at risk" Japan "at risk" South Korea "at risk"Other HI income 18-64 yrs "at risk"65+ yrs per countryUS >65 yrsCanada >65 yrsUK >65 yrsGermany >65 yrsFrance >65 yrsItaly >65 yrsSpain >65 yrsBelgium >65 yrsNetherlands >65 yrsGreece >65 yrsPortugal >65 yrsPoland >65 yrsOther Europe >65 yrsAustralia >65 yrsJapan >65 yrsSouth Korea >65 yrsOther HI income >65 yrsPopulations =>Births18-64 yrs65 yrs only65 yrs +Sources =>PPSV price summaryPCV and PUPV price summaryPub Priv splitAt risk groupsPipelineCompany reported sales

To order this report:: MarketVIEW: Universal pneumo vaccines



Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 +2.54 0.14%
NASDAQ 4,095.5160 +9.2910 0.23%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs